Australian GeneICE Patent Granted

For immediate release: 29th January 2008

                                  VALIRX PLC                                   

                          ("ValiRx" or the "Company")                          

                       Australian GeneICE Patent Granted                       

ValiRx (AIM: VAL), the cancer therapeutics company, today announces that its
proprietary gene-silencing technology, GeneICE, has received patent approval by
the Australian Patent Office. This follows the granting of a US patent in April
2007 and a European patent in August 2007.

ValiRx holds the rights to GeneICE through its subsidiary, Cronos Therapeutics
Ltd ("Cronos"), which has an exclusive worldwide license agreement with
Imperial College Innovations.

GeneICE compounds have the potential to freeze the development and growth of
cancerous cells and also have potential major applications in inflammatory
disease and inherited genetic conditions. Cronos' partner, Cancer Research UK,
a prestigious research institute in Europe, has recently completed phase one of
its pre-clinical trials on GeneICE through Cancer Research Technology Limited
("CRT"). In these trials, GeneICE was successfully shown to trigger cell death
in ovarian, pancreatic and prostate cancer cells and could potentially be
relevant to other cancers.

Dr Satu Vainikka, CEO of ValiRx, commented:

"This latest patent further underpins the robustness of our gene silencing
technology. Australia has one of the highest incidence rates for certain
cancers in the world."

                                   --Ends--                                    

About ValiRx plc

ValiRx is a biopharmaceutical development company that is building a portfolio
of complementary cancer-related therapeutic and diagnostic technologies. It
currently holds a worldwide exclusive license for Nucleosomics, the early stage
oncology diagnostics technology, and has majority stakes in Cronos Ltd and
ValiBIO SA:

  * Cronos holds worldwide exclusive licenses to two innovative and potentially
    market changing technologies, GeneICE and HyperGenomicsTM, and is
    developing further novel cancer therapies;
   
  * ValiBIO SA is a Belgium joint venture between ValiRx and BIO.be focusing on
    the development and commercialisation of products in the epigenomics
    sector, the first products to be put into development being HyperGenomics
    and Nucleosomics. ValiRx has a 77% majority holding in the company.
   
ValiRx is headquartered in London, England. Further information can be found at
www.valirx.com

Contact Details:

     ValiRx Plc          WH Ireland         GTH Communications    
                                                                  
  Dr Satu Vainikka     David Youngman        Toby Hall / Jade     
                                                Mamarbachi        
                                                                  
[phone]   [phone]     [phone]   
                            2174